Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
复制标题
DOI：
10.1093/neuonc/now058
复制
发表时间：
2016-09-01
期刊：
影响因子：
15.9
通讯作者：
Tonn, Joerg C.
中科院分区：
文献类型：
--
作者：
Albert, Nathalie L.;Weller, Michael;Tonn, Joerg C.
该指南提供了在胶质瘤中使用PET成像的建议。该综述考察了使用葡萄糖(F-18-FDG)和氨基酸示踪剂(C-11-MET、F-18-FET和(18)F-FDOPA)PET在脑胶质瘤患者中的临床益处。在诊断、活检和切除以及放射治疗计划、治疗监测和疗效评估方面，发表了越来越多的PET成像研究。建议是基于从研究中产生的证据，这些研究通过组织学或临床病程证实了PET的发现。该指南强调了氨基酸PET优于葡萄糖PET的PET成像的临床价值，并为使用PET辅助胶质瘤患者的治疗提供了一个框架。
This guideline provides recommendations for the use of PET imaging in gliomas. The review examines established clinical benefit in glioma patients of PET using glucose (F-18-FDG) and amino acid tracers (C-11-MET, F-18-FET, and (18) F-FDOPA). An increasing number of studies have been published on PET imaging in the setting of diagnosis, biopsy, and resection as well radiotherapy planning, treatment monitoring, and response assessment. Recommendations are based on evidence generated from studies which validated PET findings by histology or clinical course. This guideline emphasizes the clinical value of PET imaging with superiority of amino acid PET over glucose PET and provides a framework for the use of PET to assist in the management of patients with gliomas.